SHARE Adaptation Intervention for African-American Families
Adapting the SHARE for Dementia Early-Stage Dyadic Intervention: A Stage I Pilot Study With African-American Families
Benjamin Rose Institute on Aging
120 participants
Aug 19, 2025
INTERVENTIONAL
Conditions
Summary
This project aims to culturally adapt the SHARE program for African-Americans in early-moderate stage dementia and their care partner. Upon completion of the adaptation, a pilot randomized-control trial wil be confucted to compare the adaptaed SHARE program versus usual care.
Eligibility
Inclusion Criteria6
- African American dyads (both the caregivers and the care-recipient, an individual with an early-stage memory impairing condition (e.g., Alzheimer's disease, vascular dementia, cognitive impairment, etc.)
- Care-recipient lives at home.
- The caregiver (CG) and/or the person with dementia (PWD), or symptoms of memory loss must identify as African American.
- PWD must be at least 50 years old and CGs 18 or older,
- Ability to speak and read English,
- Experiencing signs and symptoms of mild to moderate dementia through family caregiver report on the Dementia Severity Rating Scale and meeting the National Institute on Aging and the Alzheimer's Association clinical criteria for probable AD.
Exclusion Criteria4
- A mental health condition (e.g., schizophrenia, bipolar disorder, major depression)
- A traumatic brain injury
- Intellectual or developmental disability
- Individuals experiencing extreme difficulty adjusting and coping to the diagnosis • Individuals living in an institutional setting
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
The intervention group will receive the adapted SHARE Dyadic program, consisting of five, 60-90-minute curriculum-guided sessions with a SHARE Counselor, plus one optional family session.
Control group participants will receive a treatment as usual equivalent: a single, standardized educational and resource session with a packet of information.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07208162